The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity

被引：0

作者：

Kuchroo, Juhi R. ^{[1
,2
,3
]}

Hafler, David A. ^{[4
,5
,6
]}

Sharpe, Arlene H. ^{[1
,2
,3
,6
,7
,8
]}

Lucca, Liliana E. ^{[4
,5
]}

机构：

[1] Harvard Med Sch, Dept Immunol, Blavatnik Inst, Boston, MA 02115 USA

[2] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[4] Yale Sch Med, Dept Neurol, New Haven, CT 06510 USA

[5] Yale Sch Med, Dept Immunobiol, New Haven, CT 06510 USA

[6] Broad Inst MIT & Harvard Univ, Cambridge, MA USA

[7] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[8] Harvard Med Sch, Boston, MA 02115 USA

来源：

SCIENCE IMMUNOLOGY | 2021年 / 6卷 / 65期

关键词：

T-CELL EXHAUSTION; REGULATORY T; INHIBITORY RECEPTORS; PHOSPHOINOSITIDE; 3-KINASE; COINHIBITORY PATHWAYS; PROGRAMMED DEATH-1; IMMUNE-RESPONSE; GUT MICROBIOTA; ADVERSE EVENTS; CUTTING EDGE;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune checkpoint blockade has demonstrated success in treating cancer but can lead to immune-related adverse events (irAEs), illustrating the centrality of these pathways in tolerance. Here, we describe programmed cell death protein 1 (PD-1) control of T cell responses, focusing on its unique restraint of regulatory T cell function. We examine successes and limitations of checkpoint blockade immunotherapy and review clinical and mechanistic features of irAEs. Last, we discuss strategies to modulate PD-1 blockade to enhance antitumor immunity while limiting autoimmunity.

引用

页数：15

共 194 条

[1] MECHANISMS OF DISEASE Inflammatory Bowel Disease [J].

Abraham, Clara ;

Cho, Judy H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) :2066-2078

[2] Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy [J].

Ahmad, Shamim ;

Abu-Eid, Rasha ;

Shrimali, Rajeev ;

Webb, Mason ;

Verma, Vivek ;

Doroodchi, Atbin ;

Berrong, Zuzana ;

Samara, Raed ;

Rodriguez, Paulo C. ;

Mkrtichyan, Mikayel ;

Khleif, Samir N. .

CANCER RESEARCH, 2017, 77 (08) :1892-1904

[3] Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[4] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[5] Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups [J].

Andrews, Lawrence P. ;

Yano, Hiroshi ;

Vignali, Dario A. A. .

NATURE IMMUNOLOGY, 2019, 20 (11) :1425-1434

[6] A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases [J].

Angin, Mathieu ;

Brignone, Chrystelle ;

Triebel, Frederic .

JOURNAL OF IMMUNOLOGY, 2020, 204 (04) :810-818

[7] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[8] Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones [J].

Ausubel, LJ ;

Kwan, CK ;

Sette, A ;

Kuchroo, V ;

Hafler, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (26) :15317-15322

[9] Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology [J].

Autio, Karen A. ;

Boni, Valentina ;

Humphrey, Rachel W. ;

Naing, Aung .

CLINICAL CANCER RESEARCH, 2020, 26 (05) :984-989

[10] CD4+CD25high regulatory cells in human peripheral blood [J].

Baecher-Allan, C ;

Brown, JA ;

Freeman, GJ ;

Hafler, DA .

JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253

← 1 2 3 4 5 6 7 8 9 10 →